Chemotherapy of human African trypanosomiasis: current and future prospects

TY - JOUR

T1 - Chemotherapy of human African trypanosomiasis

T2 - current and future prospects

AU - Fairlamb, Alan H.

N1 - Funding Information: A.H.F. thanks the Wellcome Trust for support under the Principal Research Fellowship Scheme.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Three of the four currently approved drugs for the treatment of African trypanosomiasis (sleeping sickness) were developed over 50 years ago. All of the current therapies are unsatisfactory for various reasons, including unacceptable toxicity, poor efficacy, undesirable route of administration, and drug resistance. The possible modes of action of these drugs are briefly reviewed, as are the possible mechanisms of resistance. The intermediate and long-term prospects for the development of safer, effective drugs are discussed.

AB - Three of the four currently approved drugs for the treatment of African trypanosomiasis (sleeping sickness) were developed over 50 years ago. All of the current therapies are unsatisfactory for various reasons, including unacceptable toxicity, poor efficacy, undesirable route of administration, and drug resistance. The possible modes of action of these drugs are briefly reviewed, as are the possible mechanisms of resistance. The intermediate and long-term prospects for the development of safer, effective drugs are discussed.

UR - https://www.scopus.com/pages/publications/0142258170

U2 - 10.1016/j.pt.2003.09.002

DO - 10.1016/j.pt.2003.09.002

M3 - Review article

C2 - 14580959

AN - SCOPUS:0142258170

SN - 1471-4922

VL - 19

SP - 488

EP - 494

JO - Trends in Parasitology

JF - Trends in Parasitology

IS - 11

ER -